Dissecting the immunogenotypic basis of type I InterFeroNs-driven PSOriasis – DIFN-PSO
We recently identified by investigating a Mendelian psoriasis model a new mutatioon of a gene encoding a protein involved in skin immune responses, which leads to a constitutive activation of the related signaling pathway. By gathering a consortium with high level complementary expertises, we plan not only to demonstrate the pathogenicity of this mutation in psoriasis, but also to identify robust immunogenetic biomarkers applicable in practice to better predict the clinical response to different therapies, allowing to design innovative precision medical approaches, which would bring multiple benefits for patients affected with this chronic inflammatory disease still associated with high rates of loss of efficacy in real life, including for the most effective treatments to date.
Project coordination
Hervé BACHELEZ (Institut des Maladies Génétiques)
The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.
Partner
IMAGINE INSTITUT DES MALADIES GÉNÉTIQUES (IHU)
IMAGINE INSTITUT DES MALADIES GÉNÉTIQUES (IHU)
HIPI Human Immunology, Pathophysiology and Immunotherapy / Immunologie humaine, physiopathologie & immunithérapie
Institut Imagine - U1163 Institut des Maladies Génétiques
Help of the ANR 597,454 euros
Beginning and duration of the scientific project:
November 2021
- 42 Months
